Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland

• Príomhchruthaitheoirí: André B. Kind (Údar), Andrew Pavelyev (Údar), Smita Kothari (Údar), Nadia El Mouaddin (Údar), Aurélie Schmidt (Údar), Edith Morais (Údar), Patrik Guggisberg (Údar), Florian Lienert (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: BMC, 2020-05-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Abstract Background An infection with high-risk human papillomavirus (HPV) is the obligatory aetiological factor for the development of cervical cancer. In Switzerland, the prevention strategy for cervical cancer is based on primary prevention via HPV vaccination and secondary prevention with an opp...